Our data suggest that inhibition of CTSD and LOXL2 would not only have an anti-proliferative effect but may also be an effective therapeutic approach for eradicating residual disseminated tumor cells or maintaining them in a dormant state to avert cancer recurrence. Here, LOXL2 is linked to neoplasm.